You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

CDK 4 and 6 Inhibition in Breast Cancer

The treatment of HR-positive breast cancer is undergoing significant changes with the introduction of novel targeted therapies such as cyclin-dependent kinase (CDK) 4 and 6 inhibitors that are already demonstrating improvements in patient outcomes. As different agents become available and are increasingly integrated into treatment algorithms, clinical challenges are created regarding rational treatment selection, appropriate patient selection, and sequencing of treatments.

Supported by an independent educational sponsorship from

Eli Lilly and Company

CME Activities

See All

Polling Question

You must log in to answer this question
How familiar are you with the proper dose adjustments necessary for patients experiencing early-onset diarrhea while taking abemaciclib?
Very familiar
Somewhat familiar
Not at all familiar

Related Resources

Downloadable Slide Kit

Highlights of Clinical Data in CDK4/6 Inhibition in Breast Cancer


Clinical Articles

Breast cancer  

Cancer treatment reviews  

Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer  

Related Links

See All

Steering Committee

Peter Schmid, MD, PhD

Steering Committee Chair

Centre for Experimental Cancer Medicine
St. Bartholomew Hospital
Chair of Cancer Medicine and Honorary Consultant in Medical Oncology Barts Cancer Institute
Queen Mary University London
London, United Kingdom

Giuseppe Curigliano, MD, PhD

Giuseppe Curigliano, MD, PhD

Professor, University of Milano; Head, European Institute of Oncology, Milan, Italy

Joyce O'Shaughnessy, MD

Joyce O'Shaughnessy, MD

Celebrating Women’s Chair in Breast Cancer
Baylor University Medical Center
Texas Oncology
US Oncology
Dallas, Texas, United States

Guy Jerusalem, MD, PhD

Guy Jerusalem, MD, PhD

Head, Medical Oncology, CHU Sart Tilman Liège; Professor of Medical Oncology, Liège University, Liège, Belgium

Sibylle Loibl, MD, PhD

Sibylle Loibl, MD, PhD

Chair German Breast Group, Sana Kliniken Offenbach, Breast Cancer Center; Associate Professor, University Frankfurt am Main, Frankfurt, Germany